What is Ivermectin?
Ivermectin is a potent medication that belongs to the avermectin class of drugs, specifically a semi-synthetic derivative of the macrocyclic lactone, abamectin. Primarily known for its powerful antiparasitic properties, Ivermectin has been a cornerstone in treating a wide range of parasitic infections in both humans and animals for decades. While its primary classification is as an antiparasitic agent, its antiviral potential has also garnered significant research interest.
In its generic form, the drug is known as Ivermectin. It is also available under various brand names, with Stromectol being one of the most recognized for human use. In veterinary medicine, brand names such as Heartgard and Ivomec are widely used. The discovery of Ivermectin revolutionized the treatment of diseases like onchocerciasis (river blindness) and strongyloidiasis, earning Satoshi Ōmura and William C. Campbell the Nobel Prize in Physiology or Medicine in 2015 for their contributions to its development and application.
Mechanism of Action
Ivermectin's efficacy stems from its ability to disrupt the cellular functions of parasites, leading to their paralysis and death. At the molecular level, its primary mechanism involves binding to glutamate-gated chloride channels (GluCls) and gamma-aminobutyric acid (GABA)-gated chloride channels, which are crucial for neurotransmission in invertebrates.
In parasites, these channels are integral to nerve and muscle cell function. When Ivermectin binds to these channels, it increases the permeability of the cell membrane to chloride ions. This influx of chloride ions causes hyperpolarization of the cell, effectively paralyzing the parasite by inhibiting neuromuscular transmission. Muscles become flaccid, and the parasite is unable to move or feed, eventually leading to its demise.
Crucially, Ivermectin exhibits a much higher affinity for invertebrate chloride channels than for mammalian ones. This selectivity is a key factor in its therapeutic index, meaning it is generally safe for humans and animals when used as directed, as it has minimal impact on host nervous systems.
Beyond its direct action on chloride channels, research suggests Ivermectin may also interfere with other cellular processes in parasites, including nuclear and mitochondrial functions, further contributing to its antiparasitic activity. Its potential antiviral activity is thought to involve mechanisms such as inhibiting viral import into the host cell, blocking viral replication, or interfering with viral protein synthesis, though these mechanisms are still under extensive investigation and are not the primary basis for its approved uses.
Clinical Uses & Indications
Ivermectin is FDA-approved for the treatment of several parasitic infections. Its most prominent approved uses include:
- Onchocerciasis (River Blindness): Caused by the filarial worm Onchocerca volvulus, this disease can lead to severe itching, skin lesions, and irreversible blindness. Ivermectin is the drug of choice for mass treatment programs.
- Strongyloidiasis: An intestinal parasitic infection caused by Strongyloides stercoralis, which can lead to gastrointestinal symptoms, rash, and pulmonary complications.
- Scabies: A highly contagious skin infestation caused by the mite Sarcoptes scabiei. While topical treatments are often preferred, oral Ivermectin is effective for severe or widespread infestations and for treating contacts.
- Pediculosis Capitis (Head Lice): Although topical treatments are common, Ivermectin lotion is approved for treating head lice when topical treatments have failed.
Off-Label and Investigational Uses:
Ivermectin has also been investigated for other conditions, including:
- Lymphatic Filariasis: While not a primary treatment, it can be used in combination therapy in certain regions.
- Cutaneous Larva Migrans: A parasitic skin infection caused by hookworm larvae.
- Various other helminthic infections.
It is important to note that while Ivermectin has been studied for antiviral properties, including against SARS-CoV-2, these uses are generally considered off-label and have not received broad regulatory approval for these indications due to insufficient robust clinical evidence of efficacy and safety.
Dosage & Administration
Ivermectin is available in several dosage forms, primarily oral tablets and topical lotions or creams. The dosage and administration route depend heavily on the condition being treated, the patient's weight, and the specific indication.
Oral Ivermectin
Oral Ivermectin is typically administered as a single dose or a series of doses, depending on the parasitic infection. Dosing is usually weight-based, often calculated in milligrams per kilogram (mg/kg) of body weight.
- Onchocerciasis: A common regimen is 150 mcg/kg body weight, administered orally every 6 or 12 months.
- Strongyloidiasis: Typically 200 mcg/kg body weight, administered orally as a single dose. Retreatment may be necessary in some cases.
- Scabies: Usually 200 mcg/kg body weight, administered orally as a single dose. A second dose may be given 1-2 weeks later if needed.
Tablets should be taken on an empty stomach with a full glass of water. For scabies, it is often recommended to take the dose with food to enhance absorption.
Topical Ivermectin
Topical formulations are used for specific conditions:
- Head Lice: Ivermectin lotion (0.5%) is applied to dry hair and scalp, left on for a specified duration (e.g., 10 minutes), and then rinsed out. It is typically not washed out for a further 24 hours. It is applied once, with a second application possibly needed if live lice are observed 7 days after the first treatment.
- Scabies: Topical Ivermectin creams are less common than oral formulations for scabies but may be used in specific clinical contexts.
Important Considerations:
- Always follow the prescribed dosage and administration instructions from a healthcare professional.
- Self-medication with Ivermectin, especially using veterinary formulations, is strongly discouraged due to risks of toxicity and incorrect dosing.
Side Effects & Safety
Ivermectin is generally well-tolerated when used at recommended doses for approved indications. However, like all medications, it can cause side effects.
Common Side Effects
These are typically mild and transient:
- Dizziness
- Nausea
- Diarrhea
- Headache
- Fatigue
- Abdominal pain
- Rash or itching (especially during treatment for onchocerciasis, often related to the death of microfilariae)
Serious Side Effects
Serious side effects are rare but can occur, particularly with high doses or in individuals with certain underlying conditions:
- Neurological effects: Encephalopathy (brain dysfunction), tremors, ataxia (loss of coordination), seizures, coma. These are more likely with overdoses or in individuals with impaired blood-brain barrier function.
- Hypotension: Low blood pressure.
- Hepatotoxicity: Liver damage, though rare.
- Severe skin reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported rarely.
Mazzotti Reaction: In patients being treated for onchocerciasis, rapid death of microfilariae can trigger a reaction characterized by fever, itching, rash, joint pain, and sometimes lymphadenitis or peripheral edema. This reaction is typically managed symptomatically.
Contraindications and Precautions
Ivermectin is contraindicated in individuals with known hypersensitivity to the drug or its components.
- Pregnancy: While considered safe in certain low-dose, single-treatment scenarios for specific indications, it should generally be avoided during pregnancy unless the potential benefit justifies the potential risk to the fetus.
- Lactation: Ivermectin is excreted in breast milk. Caution is advised, and consultation with a healthcare provider is recommended.
- Impaired Blood-Brain Barrier: Patients with conditions that compromise the blood-brain barrier (e.g., certain neurological diseases, concurrent use of certain other medications) may be at increased risk of central nervous system side effects.
- Co-infection with Loa loa: In individuals with high microfilaremia of Loa loa, Ivermectin can potentially cause severe or fatal encephalopathy. Screening for Loa loa is recommended in endemic areas before treatment.
Drug Interactions
Ivermectin has a relatively low potential for significant drug interactions, especially when used for its approved indications at recommended doses. However, some interactions are possible:
- Central Nervous System (CNS) Depressants: Concomitant use with other CNS depressants (e.g., benzodiazepines, barbiturates, alcohol) may potentiate sedative effects and increase the risk of neurological side effects.
- Warfarin: There have been rare reports of increased INR and bruising in patients taking Ivermectin and Warfarin. Close monitoring of INR is recommended if co-administration is necessary.
- P-glycoprotein (P-gp) Substrates: Ivermectin is a substrate for P-gp, a drug efflux transporter. Drugs that inhibit P-gp (e.g., verapamil, quinidine) could potentially increase Ivermectin levels, although the clinical significance is not well-established for typical doses. Conversely, drugs that induce P-gp might decrease Ivermectin levels.
- Other Avermectins: Concurrent use with other avermectin derivatives should be approached with caution.
It is crucial to inform your healthcare provider about all medications, supplements, and herbal products you are currently taking to ensure safe use of Ivermectin.
Molecular Properties
Ivermectin is a complex macrocyclic lactone derivative. Its molecular structure is derived from avermectin B1, which is a mixture of two homologues: avermectin B1a and avermectin B1b.
| Molecular Formula | C48H74O14 (for avermectin B1a, the major component) |
| Molecular Weight | 875.09 g/mol (for avermectin B1a) |
| Chemical Class | Macrocyclic lactone, Avermectin |
| Structure Description | Ivermectin is characterized by a 16-membered macrocyclic lactone ring. It features a disaccharide moiety attached to the ring, with a spiroketal system. The molecule is highly lipophilic and contains multiple chiral centers, contributing to its complex three-dimensional structure and specific receptor binding. The SMILES notation provides a linear representation of this complex structure. |
| SMILES Notation | CC[C@@H](C)[C@@H]1OC(=O)[C@H](C)/C=C/C=C/[C@@H](O[C@@H]2O[C@@H](C)C[C@@H](OC)[C@H]2O)CC/C=C/C=C\C(=O)O[C@H](C(C)C)CC1 |
The SMILES (Simplified Molecular Input Line Entry System) string CC[C@@H](C)[C@@H]1OC(=O)[C@H](C)/C=C/C=C/[C@@H](O[C@@H]2O[C@@H](C)C[C@@H](OC)[C@H]2O)CC/C=C/C=C\C(=O)O[C@H](C(C)C)CC1 precisely describes the connectivity and stereochemistry of the Ivermectin molecule, enabling computational analysis and representation.
Analyze Ivermectin with MolForge
Understanding the intricate molecular properties of drugs like Ivermectin is fundamental to advancing pharmaceutical research and drug discovery. MolForge's AI-powered platform offers powerful tools to delve deeper into the characteristics of such complex molecules. From exploring detailed structural analyses and predicting potential interactions to simulating pharmacokinetic properties, MolForge empowers researchers to accelerate their discovery pipelines.
Whether you are investigating Ivermectin's established mechanisms, exploring its potential in new therapeutic areas, or designing novel drug candidates, MolForge can provide the insights you need. Discover the future of molecular discovery by exploring Ivermectin and countless other compounds on the MolForge platform today. Visit our dashboard to begin your analysis and unlock groundbreaking research possibilities.